Hinova Pharmaceuticals, Inc.SSE: 688302

Voluntary Disclosure on Obtaining the Notice of Approval for Clinical Trial of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

· Issued by Hinova Pharmaceuticals, Inc. via Shanghai Stock Exchange

On 6ix: 6ix.com/news/voluntary-disclosure-on-obtaining-the-notice-of-approval-for-clinical-trial-of-oral-protac-drug-hp568-tablets-in-the-treatment-of-erher2-advanced-breast-cancer

Voluntary Disclosure on Obtaining the Notice of Approval for Clinical Trial of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Hinova Pharmaceuticals, Inc. on 6ix

Earlier from Hinova Pharmaceuticals

Later from Hinova Pharmaceuticals

All Hinova Pharmaceuticals news releases